{"id":249733,"date":"2023-12-05T00:00:00","date_gmt":"2023-12-05T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0029-2023-biopharma-psoriasis-access-reimbursement-detailed\/"},"modified":"2026-04-21T11:16:45","modified_gmt":"2026-04-21T11:16:45","slug":"acreim0029-2023-biopharma-psoriasis-access-reimbursement-detailed-expanded-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0029-2023-biopharma-psoriasis-access-reimbursement-detailed-expanded-analysis\/","title":{"rendered":"Psoriasis &#8211; Access &#038; Reimbursement &#8211; Detailed, Expanded Analysis"},"content":{"rendered":"<p>2023 marks a pivotal year for the autoimmune space as numerous releases of biosimilar adalimumab challenge the market dominance of AbbVie\u2019s Humira, one of the best-selling brands in the United States. The entry of Amgen\u2019s Amjevita and the first interchangeable biosimilar, Boehringer Ingelheim\u2019s Cyltezo, as well as adalimumab biosimilars from several other manufacturers, will have broad-ranging implications for Humira and likely other <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors in the treatment of rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>), psoriasis, ulcerative colitis (<abbr title=\"ulcerative colitis\">UC<\/abbr>), and Crohn\u2019s disease (<abbr title=\"Crohn's disease\">CD<\/abbr>). This report explores specialists\u2019 receptivity to biosimilars for these indications and <abbr title=\"managed care organization\">MCO<\/abbr>s\u2019 coverage policies affecting Humira, its biosimilars, and other key brands in their largest fully insured commercial plans.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How will the market entry of multiple biosimilars of adalimumab affect <abbr title=\"managed care organization\">MCO<\/abbr> tiering and restrictions on Humira and other <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>, psoriasis, <abbr title=\"ulcerative colitis\">UC<\/abbr>, and <abbr title=\"Crohn's disease\">CD<\/abbr>?<\/li>\n<li>Will <abbr title=\"managed care organization\">MCO<\/abbr>s limit the biosimilars they cover or prefer, and what factors will most influence <abbr title=\"managed care organization\">MCO<\/abbr>s\u2019 selection of preferred biosimilars?<\/li>\n<li>Under what circumstances and to what types of patients will physicians be most likely to prescribe a biosimilar, and how will they choose among the available products? How important is an interchangeable designation?<\/li>\n<li>Will prescribers specifically request that pharmacies dispense Humira to blunt an automatic substitution with an interchangeable biosimilar?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geography: United States.<\/p>\n<p>Primary research: Survey of 102 U.S. rheumatologists; survey of 41 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr title=\"pharmacy director\">PD<\/abbr>s \/ <abbr title=\"medical director\">MD<\/abbr>s). Limited results from prior surveys of 101 gastroenterologists and 101 dermatologists.<\/p>\n<p>Key drugs covered: Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, Yusimry<\/p>\n<p>Key analysis provided:<\/p>\n<ul class=\"round-bullets\">\n<li>Reimbursement and contracting<\/li>\n<li>Access and prescribing<\/li>\n<li>Opportunities and challenges for biosimilars in 2024 and beyond<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-249733","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249733\/revisions"}],"predecessor-version":[{"id":576032,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249733\/revisions\/576032"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}